The Latest in Transplant

ALL: When Should MRD Trigger Stem Cell Transplants?

January 29, 2024

In Transplant-Ineligible Myeloma, This Frontline Tx Is Better

December 15, 2023

GVHD raises vitiligo risk in transplant recipients

December 15, 2023

No Benefit to Salvage Transplant in R/R Multiple Myeloma

December 14, 2023

MRD status predicts transplant benefit in NPM1-mutated AML

December 13, 2023

Sickle Cell: Good Outcomes for Haploidentical Transplants

December 12, 2023

Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

December 11, 2023

Hematology is in the Brodsky family’s blood

December 6, 2023

ASH 2023: Equity, Sickle Cell, and Real-Life Outcomes

December 4, 2023

Trial shows utility of small-volume blood collection tubes

November 14, 2023

Transplant

DLBCL treatment options: CAR T outperforms ASCT

November 3, 2023

Frontline myeloma treatments: ASCT vs. CAR T

October 25, 2023

Dispelling clinicians’ misconceptions about sickle cell disease

September 28, 2023

FDA approves motixafortide for stem cell mobilization in myeloma

September 11, 2023

Is additional treatment needed, pretransplant, for r/r AML?

September 11, 2023